Overview

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Status:
Completed

Trial end date:
2013-04-15

Target enrollment:

Participant gender:

Summary

To estimate the difference in efficacy and safety of bevacizumab and RAD001 compared to bevacizumab and interferon alfa-2a for first-line treatment of patients with metastatic carcinoma of the kidney.

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Collaborator:

Roche Pharma AG

Treatments:

Bevacizumab
Everolimus
Interferon alpha-2
Interferon-alpha
Interferons
Sirolimus